Answer:
B
Explanation:
Firstly, we will need to calculate the number of moles. To do this, we make use of the ideal gas equation
PV = nRT
n = PV/RT
The parameters have the following values according to the question:
P = 780mmHg, we convert this to pascal.
760mHG = 101325pa
780mmHg = xpa
x = (780 * 101325)/760 = 103,991 Pa
V= 400ml = 0.4L
T = 135C = 135 + 273.15 = 408.15K
n = ?
R = 8314.463LPa/K.mol
Substituting these values into the equation yields the following:
n = (103991 * 0.4)/(8314.463 * 408.15)
= 0.012 moles
Now we know 1 mole contains 6.02 * 10^23 molecules, hence, 0.012moles will contain = 0.012 * 6.02 * 10^23 = 7.38 * 10^21 molecules
Answer:
K remains the same;
Q < K;
The reaction must run in the forward direction to reestablish the equilibrium;
The concentration of 
will decrease.
Explanation:
In this problem, we're adding an excess of a reactant, chlorine gas, to a system that is already at equilibrium. According to the principle of Le Chatelier, when a system at equilibrium is disturbed, the equilibrium shifts toward the side of the equilibrium that minimizes the disturbance.
Since we'll have an excess of chlorine, the system will try to reduce that excess by shifting the equilibrium to the right. Therefore, the reaction must run in the forward direction to reestablish the equilibrium.
The value of K remains the same, as it's only temperature-dependent, while the value of Q will be lower than K, that is, Q < K, as Q < K is the case when reaction proceeds to the right.
As a result, since is also a reactant, its concentration will decrease.
Answer : It increases
Rusting is where oxygen binds to iron and forms iron oxide.
So once iron rusts, there is oxygen, just not in air; it's in the iron oxide.
All reactions are reversible, albeit at different rates (the "irreversible" ones are still reversible, but much slower given that they take so much collision luck and energy.
Answer:
Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation.
Explanation:
